Ablynx NV - Daan Hooreweghe

Views:
 
Category: Entertainment
     
 

Presentation Description

No description available.

Comments

Presentation Transcript

conclusion:

Ablynx NV

conclusion:

General information Why would you invest? S tock information Cash flow statement Balance sheet News Conclusion C ontent

conclusion:

Zwijnaarde , Ghent Biopharmaceutical company Devoloping Nanobodies General information

conclusion:

Stock information Cash flow statements Balance sheet Why would you invest ?

conclusion:

Stock information Total amount of capital: 140 671 002,58 euro Total number of shares: 75 253 667 American Depositary Receipt (ADR): dollar-denominated securities

conclusion:

Cash used in operating activities Revenue of the activities from a company Cash flow statements

conclusion:

Cash flow from investing activities Reports aggregate change in cash position Cash flow statements

conclusion:

Cash flow from financing activities Shows the source of a company’s financing and capital Cash flow statements

conclusion:

Assets What the company uses to operate its business Balance sheet

conclusion:

Equity and liabilities The initial amount of money invested into a business Balance sheet

conclusion:

BEL 20 Take the place of Bekaert Short time in the BEL20 Sanofi 3,9 milliard euro - 45 euro/stake Stakes went up News

conclusion:

Investing would be a risk Investing in the future Making less profit High equity from investors Stocks are still rising What with the bid of Sanofi? conclusion

authorStream Live Help